1. Home
  2. ZKH vs CRVS Comparison

ZKH vs CRVS Comparison

Compare ZKH & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZKH

ZKH Group Limited

HOLD

Current Price

$3.39

Market Cap

587.4M

Sector

N/A

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$6.53

Market Cap

546.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZKH
CRVS
Founded
1998
2014
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
587.4M
546.7M
IPO Year
2023
2016

Fundamental Metrics

Financial Performance
Metric
ZKH
CRVS
Price
$3.39
$6.53
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$13.75
AVG Volume (30 Days)
174.8K
1.6M
Earning Date
11-20-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,236,195,501.00
N/A
Revenue This Year
$2.58
N/A
Revenue Next Year
$10.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$2.54
52 Week High
$3.90
$9.60

Technical Indicators

Market Signals
Indicator
ZKH
CRVS
Relative Strength Index (RSI) 49.23 33.71
Support Level $3.09 $6.39
Resistance Level $3.56 $7.18
Average True Range (ATR) 0.22 0.43
MACD -0.03 -0.08
Stochastic Oscillator 35.19 9.56

Price Performance

Historical Comparison
ZKH
CRVS

About ZKH ZKH Group Limited

ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: